SCHEMBL478031

SCHEMBL478031

NC(C=O)CC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7385402 1.00
SCHEMBL5263410 0.81
SCHEMBL127428 0.77
SCHEMBL2031005 0.75
SCHEMBL6559753 0.75
SCHEMBL432922 0.75
SCHEMBL16613711 0.73
SCHEMBL127505 0.72 SLC6A2 (0.31)
SCHEMBL127666 0.72
SCHEMBL14536622 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1098256-C Substd. benzenesulfonamide derivs as prodrugs of COX-2 inhibitors SEARLE & CO (US) 2003-01-08 CN claimed
CN-1216043-A Substd. benzenesulfonamide derivs as prodrugs of COX-2 inhibitors SEARLE & CO (US) 1999-05-05 CN claimed
US-4863479-A Process for obtaining synthetic hides similar to natural hides by a chemical treatment of synthetic sheet material LORICA S.P.A. (IT) 1989-09-05 US claimed
WO-2024097731-A2 METHODS FOR TREATING COVID-19 MEDSTAR HEALTH, INC. (US) 2024-05-10 WO disclosed
US-20230364054-A1 METHODS FOR TREATING COVID-19 MEDSTAR HEALTH, INC. 2023-11-16 US disclosed
WO-2023196629-A1 BENZO[H]QUINAZOLINE-4-AMINE DERIVATIVES FOR THE TREATMENT OF CANCER Redona Therapeutics, Inc. (US) 2023-10-12 WO disclosed
US-11654132-B2 Methods for treating COVID-19 MEDSTAR HEALTH, INC. (US) 2023-05-23 US disclosed
EP-4143204-A1 METHODS FOR TREATING COVID-19 Medstar Health, Inc. (US) 2023-03-08 EP disclosed
WO-2023287836-A1 LIQUID LAUNDRY DETERGENT FORMULATION DOW GLOBAL TECHNOLOGIES LLC (US) 2023-01-19 WO disclosed
WO-2023287837-A1 CLEANING BOOSTER DOW GLOBAL TECHNOLOGIES LLC (US) 2023-01-19 WO disclosed
US-20220395488-A1 METHODS FOR TREATING COVID-19 MEDSTAR HEALTH, INC. 2022-12-15 US disclosed
EP-1086108-A1 HETEROBICYCLIC AND TRICYCLIC NITRIC OXIDE SYNTHASE INHIBITORS G.D. Searle &amp; Co. (US) 2001-03-28 EP disclosed
EP-0567975-B1 Process for rapid dyeing of composite synthetic sheet material designed to imitate natural leather LORICA SUD S R L (IT) 2000-07-26 EP disclosed
WO-1999064426-A1 HETEROBICYCLIC AND TRICYCLIC NITRIC OXIDE SYNTHASE INHIBITORS G.D. SEARLE & CO. (US) 1999-12-16 WO disclosed
CN-1216043-A Substd. benzenesulfonamide derivs as prodrugs of COX-2 inhibitors SEARLE & CO (US) 1999-05-05 CN disclosed
EP-0567975-A1 Process for rapid dyeing of composite synthetic sheet material designed to imitate natural leather LORICA S.p.A. (IT) 1993-11-03 EP disclosed
EP-0164076-B1 PROCESS FOR PRODUCING ARTIFICIAL LEATHER SIMILAR TO REAL LEATHER BY CHEMICALLY PROCESSING SYNTHETIC SHEET MATERIALS Lorica S.p.A. (IT) 1989-12-13 EP disclosed
US-4863479-A Process for obtaining synthetic hides similar to natural hides by a chemical treatment of synthetic sheet material LORICA S.P.A. (IT) 1989-09-05 US disclosed
US-4766014-A TREATING WITH METAL SALT SOLUTION AND FATTY EMULSION LORICA S.P.A. (IT) 1988-08-23 US disclosed
EP-0164076-A2 Process for producing artificial leather similar to real leather by chemically processing synthetic sheet materials Lorica S.p.A. (IT) 1985-12-11 EP disclosed